New Drug Early Phase Development

By integrating resources such as registration, medical, Phase I center, and PK testing lab, CR Medicon is able to complete high-quality new drug early phase research.

Integrated Services & Advantages

  • Create a collaborative and rapid advancement plan through all steps, from pre-IND meetings, protocol drafting, pre-IRB review and IND filing, to the first subject recruited into the test group.
  • Partnered with multiple Phase I Centers in China, we conduct early clinical studies with various complexities and indications, with rapid trial initiation and rapid subject enrollment. 
  • Our Phase I Center in Baltimore, USA, provides early-stage research in new drug development towards US FDA submission.
  • Fully meeting all FDA GLP requirements, CR Medicon's own biological sample analysis and testing lab enables rapid method development. Operating with high-sensitivity analytical instruments, we fully meet the requirements of new drug and metabolite detection and performs rapid analysis of each sample batch.
  • Our one-stop service system enables effective collaboration of multiple functional teams to accelerate project progress
微信公众号